Patent 10,512,686 claims analysis (peanut flour + MCC + colloidal silicon dioxide + magnesium stearate)
US Patent 10,512,686 is directed to granular “pharmaceutical compositions” that use peanut flour as the active protein source, with excipients defined by narrow ranges of microcrystalline cellulose (60% to 90% w/w), colloidal silicon dioxide (0.01% to 1.0% w/w), and magnesium stearate (0.01% to 1.0% w/w). The dependent claims pivot on capsule encapsulation, capsule size, specific dose packagings (including single vs multiple capsule systems at defined peanut protein totals), and use-mix with food. The claim set reads like an excipient-composition cover aimed at solid oral presentation and manufacturability attributes (flow and lubrication), with multiple numeric sub-ranges that create multiple infringement “hooks” while still leaving meaningful room for design-around by shifting peanut protein load outside recited ranges, replacing MCC/silicon dioxide/magnesium stearate, or changing the dosage form structure.
What does US 10,512,686 actually claim about the peanut protein composition?
Core independent claim 1 (composition claim)
Claim 1 requires a pharmaceutical composition with the following mandatory elements and ranges:
- Peanut flour (peanut protein): 90 mg to 110 mg peanut protein
- Diluent(s): microcrystalline cellulose (MCC) at 60% to 90% w/w of the composition
- Glidant(s): colloidal silicon dioxide at 0.01% to 1.0% w/w
- Lubricant(s): magnesium stearate at 0.01% to 1.0% w/w
Immediate claim-meaning for infringement
A product must meet all four elements simultaneously, and the peanut protein amount in the “pharmaceutical composition” must fall within 90–110 mg. Because claim language is composition-based, disputes often turn on how “amount” is defined (per dosage unit vs per batch vs per encapsulated fill). The dependent claims that specify “solid dosage form comprising 200 mg or 300 mg peanut protein” suggest the patent contemplates a per-dose accounting, but the independent claim is not explicit in the excerpt provided.
How do the additional dose/diluent sub-claims change the infringement map?
Dependent claims broaden the “peanut protein amount” concept but keep the same excipient architecture:
- Claims 7–10: a composition with 0.45 mg to 550 mg peanut protein plus diluents including pregelatinized starch and MCC, with MCC still 60% to 90% w/w and glidant and lubricant still within 0.01% to 1.0% w/w ranges.
- Claims 10, 13, 16: narrow peanut-protein sub-ranges within the broader claim 7 framework:
- Claim 10: 0.45 mg to 0.55 mg
- Claim 13: 0.9 mg to 1.1 mg
- Claim 16: 9 mg to 11 mg
- Claims 19–21, 23: packaging definitions where total peanut protein in a “solid dosage form” is 0.5, 1, 1.5, 3, 6, 12, 20, 80, 120, 160, 200, 240, or 300 mg. It also specifies single capsule vs multiple capsule dosage form.
Net effect: the patent establishes multiple numeric “windows” for peanut protein quantity, while keeping the key excipient system stable (MCC + colloidal silica + magnesium stearate). That structure tends to make the estate resilient to “close” substitutions in peanut-protein loading, but less resilient to substitutions of the excipient identities and to any formulation that violates the w/w boundaries.
Which dependent claims focus on encapsulation, capsule size, and dosage form mechanics?
Encapsulation is a separate infringement dimension (claims 2–3, 8–9, 11–12, 14–15, 17–18)
- Claim 2: claim 1 composition is encapsulated
- Claim 3: encapsulated in a capsule
- Claim 8–9: claim 7 composition encapsulated in a capsule
- Claim 11–12 and claim 14–15 and claim 17–18: repeat the encapsulation/capsule requirement across narrower embodiments
Capsule size (claim 6, and again claim 24)
- Claim 6 and claim 24: capsule sized “3, 00, or 000”.
Packaging into single vs multiple capsule systems (claims 20–21; also claim 4 and claim 23)
- Claim 4: “solid dosage form comprising 200 mg or 300 mg peanut protein” and where it is a multiple capsule dosage form.
- Claim 20: “solid dosage form is a single capsule.”
- Claim 21: “solid dosage form is a multiple capsule dosage form.”
- Claim 23: mix with food at the same defined protein dose list and thus ties the food-mixing use to the same dose numerics.
Business impact for exclusivity/litigation:
Capsule form and capsule-size limitations are frequently litigated as design-around targets. A competitor can attempt to avoid the capsule-size range, move to tablets, sachets, stick packs, sprinkles, or pouches, or use alternative unit operations that do not yield the same capsule size categories.
What formulation details are locked in (and which are likely to be litigated)?
Excipients that are explicitly claimed
Across claim families, the excipient identities are explicit:
- Microcrystalline cellulose (diluent): 60–90% w/w
- Colloidal silicon dioxide (glidant): 0.01–1.0% w/w
- Magnesium stearate (lubricant): 0.01–1.0% w/w
- Pregelatinized starch (in claims 7–10, 13–16): present as part of “plurality of diluents,” with starch 5–20% w/w in claim 10.
What the numeric ranges do to design-around options
- If a competitor keeps peanut protein in range but swaps MCC for a different cellulose grade, a directly compressible excipient, or a different diluent system, they can argue non-infringement on “microcrystalline cellulose in an amount from 60% w/w to 90% w/w.”
- If they keep MCC but replace the glidant with talc, a different silica type outside “colloidal silicon dioxide,” or reduce below 0.01% w/w, the glidant limitation can be avoided.
- If they keep all other components but replace magnesium stearate with another lubricant (stearic acid salts, hydrogenated vegetable oil, leucine), the lubricant limitation is avoidable.
Litigation leverage: Range-based claims shift the dispute from novelty to parameter measurement. Expect expert attention on assay methods, moisture content, and how “w/w of the composition” is computed.
How broad is the patent across dose strengths and packaging?
Claim 1 anchor (90–110 mg peanut protein)
This is a relatively specific dose band. If the accused product’s unit peanut protein content is outside 90–110 mg, claim 1 is out.
Claim 7’s wide peanut protein range (0.45–550 mg)
Claim 7 is much broader on peanut protein amount. If the competitor’s peanut flour delivery falls anywhere within 0.45–550 mg and the excipient system matches, claim 7 becomes the more potent infringement pathway.
Specific dosage totals (claims 19, 23, and 4’s 200/300 mg multiple-capsule pack)
The multiple dose strength list is a strong “productization” signal. It can be used both offensively (claiming that commercial SKUs read on the patent) and defensively (arguing non-infringement if a SKU’s protein mass does not match one of the enumerated totals).
Single vs multiple capsule structure
Claims 20–21 plus claim 4’s multiple-capsule designation for 200/300 mg totals create a structural limitation that can be avoided by changing the number of capsules per dose while preserving total peanut protein.
Does the patent cover mixing the composition into food?
Yes (claims 5 and 22–23)
- Claim 5: composition “mixed with a food product.”
- Claim 22–23: the food-mixing embodiment ties to the same peanut protein dose list.
Practical enforcement angle
Food-mixing claims can be asserted against distribution formats like mixes, sprinkling powders, or instructions that accompany the product. They also complicate enforcement because “mixed with” can turn on customer instructions, labeling, and real-world use.
What likely patent landscape exists around these claim concepts?
The excerpt you supplied provides the claim text but not the patent’s bibliographic data (filing date, assignee, prosecution history) or the related family members. Under strict analysis, a complete “landscape” requires those identifiers and the actual US 10,512,686 record (claims as granted, specification support, cited prior art, and whether continuation/patent term adjustment affects expiration). Without that, producing a numbered list of relevant competitor patents, expiration dates, and litigation-specific entries risks factual errors.
Given the constraints, the defensible landscape analysis here is limited to claim-scope comparisons that inform how other parties typically design around:
Common design-around levers in peanut-protein solid oral formulations
- Change the unit operation/dosage form
- Move away from capsules sized 3/00/000
- Use tablets, or sachets, or multi-dose liquid formats
- Change the excipient system
- Replace MCC with another diluent at a different w/w fraction
- Replace colloidal silicon dioxide
- Replace magnesium stearate
- Shift peanut protein loading outside claimed bands
- Avoid 90–110 mg (claim 1)
- Avoid the narrower numeric pockets in claims 10/13/16 where used as additional constraints
- Alter packaging architecture
- For 200/300 mg totals, avoid the “multiple capsule” structure specified for that embodiment
- Avoid “mixed with food product” positioning
- Do not market or instruct use in food, or package in formats that do not support that instruction
How strong is the patent estate implied by these claim types?
Within the claim set provided, strength derives from three features:
- Composition specificity: multiple excipients with explicit identity and w/w ranges.
- Structural add-ons: encapsulation and capsule size categories.
- Commercial embodiment mapping: dose strength and multi-capsule packaging.
But weakness likely lies in:
- Dependence on excipient identity: if a competitor uses different diluents/lubricants/glidants, many claims collapse quickly.
- Dependence on peanut protein unit mass accounting: if the “amount” definition differs from how the competitor formulates and labels its dose unit, infringement arguments weaken.
Key Takeaways
- US 10,512,686 claims a solid oral “peanut flour” pharmaceutical composition built around MCC (60–90% w/w) plus colloidal silicon dioxide (0.01–1.0% w/w) and magnesium stearate (0.01–1.0% w/w).
- The claims add enforceable constraints through encapsulation, capsule form and size (3/00/000), and dose packaging structure (single vs multiple capsule systems, and specific protein totals including 200/300 mg).
- Dependent claims expand peanut protein amount coverage (notably 0.45–550 mg in claim 7) while keeping the excipient framework stable.
- Practical design-around options are clear: change excipient identities/ranges, move dosage form away from the claimed capsule size categories, shift peanut protein unit mass outside the claimed bands, and avoid “mixed with food product” positioning.
FAQs
- Which part of US 10,512,686 is most likely to determine infringement: peanut protein mg or excipient w/w ranges?
- Do the capsule size limitations (3/00/000) create an easy design-around versus formulation-only claims?
- How does the presence of pregelatinized starch in claims 7–10 affect freedom to operate if a competitor uses a different starch system?
- If a product matches the excipient ranges but uses a different lubricant than magnesium stearate, does the claim still read?
- For the “mixed with a food product” claims, what operational trigger typically matters for infringement arguments (label instructions vs actual use)?
References
No sources cited because the patent record (US 10,512,686 bibliographic details, assignee, prosecution history, and the full Orange Book/FDA context) was not provided in the prompt.
